Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients

2024-514144-85-02 Protocol OLA-TMZ-RTE-01 Human pharmacology (Phase I) - Other Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 13 sites · Protocol OLA-TMZ-RTE-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruitment pending
Participants planned 91
Countries 1
Sites 13

Glioblastoma

Key facts

Sponsor
Centre Francois Baclesse
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2024-11-08
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-514144-85-02
EudraCT number
2016-003468-38
ClinicalTrials.gov
NCT03212742

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Glioblastoma

VersionLevelCodeTermSystem organ class
20.0 PT 10018336 Glioblastoma 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Francois Baclesse

Sponsor organisation
Centre Francois Baclesse
Address
3 Avenue Du General Harris, Cs 45026 Cs 45026
City
Caen Cedex 5
Postcode
14076
Country
France

Scientific contact point

Organisation
Centre Francois Baclesse
Contact name
STEFAN Dinu

Public contact point

Organisation
Centre Francois Baclesse
Contact name
STEFAN Dinu

Locations

1 EU/EEA country · 13 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Authorised, recruitment pending 91 13
Rest of world 0

Investigational sites

France

13 sites · Authorised, recruitment pending
Groupe Hospitalier Du Havre
Oncology department, 55 B Rue Gustave Flaubert, Bp 24, Le Havre Cedex
Oncopole Claudius Regaud
Radiotherapy department, 1 Avenue Irene Joliot Curie, 31100, Toulouse
Institut De Cancerologie De L Ouest
Oncology department, 15 Rue Andre Boquel, 49100, Angers
CHU De Bordeaux
Service Oncologie Médicale, 1 Rue Jean Burguet, Cs 11261, Bordeaux Cedex
Centre Leon Berard
Radiotherapy, 28 Rue Laennec, 69008, Lyon
Institut De Cancerologie De L Ouest
Service Oncologie-Radiothérapie, Boulevard Jacques Monod, 44805, Saint-Herblain Cedex
Institut Curie
Radiotherapy department, 26 Rue D Ulm, 75005, Paris
Groupe Hospitalier Bretagne Sud
Oncology, 5 Avenue Etienne Francois De Choiseul, 56100, Lorient
Centre Henri Becquerel
Centre Onclogie Medicale, Rue D Amiens, 76038, Rouen Cedex
Centre De Radiotherapie Guillaume Le Conquerant
Radiotherapie, 61 Rue Denfert Rochereau, 76600, Le Havre
Hopitaux Universitaires Pitie Salpetriere
Service Oncologie-Radiothérapie, 47 To 83 Boulevard De L Hopital, 75013, Paris
CHU De Medecine Interne
Service Oncologie Médicale, 1 Place Victor Pauchet, Bp 20075, Amiens Cedex 2
Centre Francois Baclesse
Radiotherapie, 3 Avenue Du General Harris, Cs 45026, Caen Cedex 5

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-16 France Acceptable
2024-11-08
2024-11-08
2 SUBSTANTIAL MODIFICATION SM-3 2026-03-18 France Acceptable
2026-04-10
2026-04-20